Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Van Der Meeren, Olivier; Hatherill, Mark; Nduba, Videlis; J. Wilkinson, Robert; Muyoyeta, Monde; van Brakel, Elana; Ayles, Helen; Henostroza, Germán; Thienemann, Friedrich; J. Scriba, Thomas; H. Diacon, Andreas; Blatner, Gretta; Demoitié, Marie‐Ange; Tameris, Michèle; Malahleha, Mookho; C. Innes, James; Hellström, Elizabeth; Martinson, Neil; Singh, Tina; Jacqueline Akité, Elaine; Azam, Aisha; Bollaerts, Anne; M. Ginsberg, Ann; G. Evans, Thomas; Gillard, Paul; Tait, Dereck

doi:10.1056/nejmoa1803484

Public

Phase 2b Controlled Trial of M72/AS01 E Vaccine to Prevent Tuberculosis

Published in New England Journal of Medicine • Sep 25, 2018

Authors:

Olivier Van Der Meeren

Mark Hatherill

Videlis Nduba

Abstract

BACKGROUND: A vaccine to interrupt the transmission of tuberculosis is needed. METHODS: and its efficacy against progression to bacteriologically confirmed active pulmonary tuberculosis disease. Clinical suspicion of tuberculosis was confirmed with sputum by means of a polymerase-chain-reaction test...

Subject

Medicine

Tuberculosis

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!